| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5cd84f92e5e2ff95dfd19e4e329db3b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2021-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3aae0f44f0ba6b3c635d065a95234a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5cb0938379efb264846f5ab973c38db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85adfcc8789d195e6bdd30f7cff3741a |
| publicationDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2021107436-A |
| titleOfInvention |
Anti-TFPI antibody mutant for improving pharmacokinetics with different binding in pH range |
| abstract |
PROBLEM TO BE SOLVED: To provide better prophylactic treatment for patients with moderate to severe hemophilia A and B, particularly for patients having an inhibitor against FVIII or FIX. An antibody that binds to a TFPI, inhibits the anticoagulant function of the TFPI, and has a lower affinity for the TFPI at pH 6.0 than at pH 7.4 is provided. The lower affinity at pH 6 reduces the target-mediated clearance, which is the process by which the antibody / antigen complex is taken up by endocytosis and transported to the lysosome, where both components are degraded. The circulating half-life (T1 / 2) is improved. The lower affinity at pH 6.0 results in the disruption of the complex prior to lysosomal targeting, allowing antibody recirculation. Specific modifications to antibody binding by histidine residue substitution are disclosed along with the method of use. [Selection diagram] Fig. 2 |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |